Shots:

• Instil Bio & ImmuneOnco have partnered, under which Instil secures the rights to develop & commercialize ImmueOnco’s IMM2510 & IMM27M outside Greater China, with ImmuneOnco holding onto the rights across Greater China incl. Taiwan, Macau & Hong Kong
• ImmuneOnco will get $50M upfront & near-term payments plus $2B development, regulatory & commercial milestones along with single-digit to low double-digit percentage royalties on global ex-China sales
• Both the candidates concluded dose-escalation studies in solid tumors. IMM2510 showed responses in squamous NSCLC patients who failed PD-1 inhibitors & IMM27M showed anti-tumor activity & began combination studies with IMM2510 across China in Jul 2024